Literature DB >> 18304266

Plasmodium falciparum from Pará state (Brazil) shows satisfactory in vitro response to artemisinin derivatives and absence of the S769N mutation in the SERCA-type PfATPase6.

Isabel D Ferreira1, Axel Martinelli, Louise A Rodrigues, Ediclei L do Carmo, Virgílio E do Rosário, Marinete M Póvoa, Pedro Cravo.   

Abstract

OBJECTIVE: To evaluate the in vitro efficacy of artesunate (ATN) and artemether (ATH) against Plasmodium falciparum isolates from the Brazilian Amazon state of Pará and to search for mutations and/or altered copy numbers in the putative resistance-associated pfcrt, pfmdr1 and pfATPase6 genes.
METHODS: In vitro efficacy of ATN and ATH was successfully measured in 56 freshly collected P. falciparum isolates, using a conventional WHO microtest with minor modifications. Single nucleotide polymorphisms (SNPs) in the same isolates were inspected using DNA sequencing and/or PCR-RFLP. We used real-time quantitative PCR to assess gene copy numbers.
RESULTS: ATN and ATH geometric mean IC(50)s were 0.85 nm, 95% CI (0.55-1.15) and 3.0 nm, 95% CI (1.5-4.5), respectively. There was extremely limited diversity of pfcrt and pfmdr1 genotypes and three SNPs were identified in the pfATPase6 gene: one T to A synonymous mutation at nucleotide 2694 and two non-synonymous (both G to A) mutations at nucleotides 110 and 1916, causing predicted aminoacid shifts of arginine to lysine and of glycine to aspartate, respectively. The previously reported S769N mutation was not detected in any of the isolates inspected. In addition, no gene amplifications were detected in a subset of eight isolates.
CONCLUSION: Artemisinin derivatives display satisfactory in vitro activity locally and the pfATPase6 gene is distinct from that reported in French Guiana, suggesting that those haplotypes have not been introduced regionally.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18304266     DOI: 10.1111/j.1365-3156.2007.01991.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  22 in total

1.  Spontaneous mutations in the Plasmodium falciparum sarcoplasmic/ endoplasmic reticulum Ca2+-ATPase (PfATP6) gene among geographically widespread parasite populations unexposed to artemisinin-based combination therapies.

Authors:  Kazuyuki Tanabe; Sedigheh Zakeri; Nirianne Marie Q Palacpac; Manada Afsharpad; Milijaona Randrianarivelojosia; Akira Kaneko; Aung Swi Prue Marma; Toshihiro Horii; Toshihiro Mita
Journal:  Antimicrob Agents Chemother       Date:  2010-10-18       Impact factor: 5.191

2.  Role of pfmdr1 amplification and expression in induction of resistance to artemisinin derivatives in Plasmodium falciparum.

Authors:  Marina Chavchich; Lucia Gerena; Jennifer Peters; Nanhua Chen; Qin Cheng; Dennis E Kyle
Journal:  Antimicrob Agents Chemother       Date:  2010-03-29       Impact factor: 5.191

3.  Monitoring artemisinin resistance in Plasmodium falciparum: comparison of parasite clearance time by microscopy and real-time PCR and evaluation of mutations in Pfatpase6 gene in Odisha state of India.

Authors:  Ruchi Gupta; Neelima Mishra; Ashwani Kumar; Roma Rana; Bina Srivastava; P K Tyagi; Anupkumar R Anvikar; Neena Valecha
Journal:  Parasitol Res       Date:  2015-06-27       Impact factor: 2.289

4.  In vitro-reduced susceptibility to artemether in P. falciparum and its association with polymorphisms on transporter genes.

Authors:  Carolina Bustamante; Onikepe A Folarin; Grace O Gbotosho; Camila N Batista; Elieth A Mesquita; Rodrigo M Brindeiro; Amilcar Tanuri; Claudio J Struchiner; Akintunde Sowunmi; Ayoade Oduola; Dyann F Wirth; Mariano G Zalis; Christian T Happi
Journal:  J Infect Dis       Date:  2012-05-21       Impact factor: 5.226

5.  Polymorphisms of molecular markers of antimalarial drug resistance and relationship with artesunate-mefloquine combination therapy in patients with uncomplicated Plasmodium falciparum malaria in Thailand.

Authors:  Poonuch Muhamad; Papichaya Phompradit; Wannapa Sornjai; Thunyaluk Maensathian; Wanna Chaijaroenkul; Ronnatrai Rueangweerayut; Kesara Na-Bangchang
Journal:  Am J Trop Med Hyg       Date:  2011-09       Impact factor: 2.345

6.  Molecular Surveillance of Plasmodium falciparum Drug Resistance Markers in Clinical Samples from Botswana.

Authors:  Leabaneng Tawe; Michela Menegon; Pleasure Ramatlho; Charles W Muthoga; Naledi Mutukwa; Moses Vurayai; Wame Bothudile; Thato Motshoge; Mariangela L'Episcopia; Tjantilili Mosweunyane; Ishmael Kasvosve; Carlo Severini; Giacomo M Paganotti
Journal:  Am J Trop Med Hyg       Date:  2018-12       Impact factor: 2.345

7.  Synthesis, antimalarial activity, and intracellular targets of MEFAS, a new hybrid compound derived from mefloquine and artesunate.

Authors:  Fernando de Pilla Varotti; Ana Cristina C Botelho; Anderson Assunção Andrade; Renata C de Paula; Elaine M S Fagundes; Alessandra Valverde; Lúcia M U Mayer; Jorge Souza Mendonça; Marcus V N de Souza; Núbia Boechat; Antoniana Ursine Krettli
Journal:  Antimicrob Agents Chemother       Date:  2008-08-18       Impact factor: 5.191

8.  Status of potential PfATP6 molecular markers for artemisinin resistance in Suriname.

Authors:  Malti R Adhin; Mergiory Labadie-Bracho; Stephen G Vreden
Journal:  Malar J       Date:  2012-09-11       Impact factor: 2.979

9.  Artemisinin resistance in rodent malaria--mutation in the AP2 adaptor μ-chain suggests involvement of endocytosis and membrane protein trafficking.

Authors:  Gisela Henriques; Axel Martinelli; Louise Rodrigues; Katarzyna Modrzynska; Richard Fawcett; Douglas R Houston; Sofia T Borges; Umberto d'Alessandro; Halidou Tinto; Corine Karema; Paul Hunt; Pedro Cravo
Journal:  Malar J       Date:  2013-04-05       Impact factor: 2.979

10.  Characterization of the Plasmodium falciparum sarcoplasmic/endoplasmic reticulum Ca2+-ATPase gene in samples from Equatorial Guinea before implementation of artemisinin-based combination therapy.

Authors:  Amalia Fernández-Martínez; Patricia Mula; Pedro Cravo; Pilar Charle; Aranzazu Amor; Policarpo Ncogo; Agustín Benito; Pedro Berzosa
Journal:  Am J Trop Med Hyg       Date:  2012-11-26       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.